Analyst Greg Wade at Wedbush Morgan has hiked his price target for shares of Franklin's BioMimetic to $24, almost double their opening price Wednesday. Powering that view is the company's FDA progress on a new foot product and growth possibilities in Europe. The call, which saw BioMimetic shares (Ticker: BMTI) rise 1.3 percent Tuesday, may help push the stock out of a tight three-month trading range.
Mar 17, 2010 8:47 AM
Company discusses multiple product milestones
Mar 11, 2010 8:34 PM
European regulators have given BioMimetic Therapeutics a 15-year patent on the processes used to make its bone graft products. President and CEO Sam Lynch digs it.
The barriers to competitive entry that have now been established in the two biggest health care markets in the world are an important part of our global commercialization plans. Finally, we believe this patent further strengthens our position as an innovator in the field of orthobiologics utilizing recombinant human growth factors.
Feb 2, 2010 8:52 AM
Gene Marcial talks to investors who think small-cap biotechs could be in for another good year, especially if they have treatments in clinical trials. While it's not mentioned in Marcial's piece, Franklin-based BioMimetic Therapeutics fits that bill. The company's shares (Ticker: BMTI) rose 31 percent in 2009.
Feb 1, 2010 8:28 AM
Although venture capital funding was down by roughly a third last year, the health care sector fared better than many others, according to two reports issued today. The Dow Jones VentureSource report shows venture capital firms invested $21.4 billion in U.S. companies last year – with health care firms collecting more than information technology ventures for the first time ever. There were 701 health care deals totaling $7.7 billion, a 14 percent drop from 2008, according to VentureSource. Information technology deals totaled 817 with $6.1 billion invested, a 35 percent decrease from last year. Biopharmaceutical companies got $4.2 billion from 302 deals. The PricewaterhouseCoopers MoneyTree Report and the National Venture Capital Association shows VCs invested about $17.7 billion into U.S. companies last year, down 37 percent from 2008 and the lowest level since 1997. Biotech investing, down 19 percent in dollars and deals, was the largest investment sector in its report, with $3.5 billion invested from 406 deals. The medical device sector as the third largest sector with $2.5 billion in 309 deals.
Jan 22, 2010 10:15 AM
Milt Capps reports on the budding efforts by a group of scientists to commercialize some interesting nanotechnology used to better target and dose pharmaceuticals.
Harth expressed confidence that Revalida's ability to "tailor" drug delivery to support a wide range of drugs that require "very sustained and very constant rate" of administration will soon lead to significant progress in such fields as chemotherapy for cancer patients.
Dec 17, 2009 7:40 AM
The computers at SmarTrend have uncovered some technical tells in the trading of Franklin near-neighbors Community Health Systems and BioMimetic Therapeutics. The former's shares (Ticker: CYH) could break out of a downward trend while the latter's upward momentum (Ticker: BMTI) — driven in large part by Novo's buying — may be fizzing out.
Dec 11, 2009 9:34 AM
Novo A/S, the Danish health care conglomerate that owns 17 percent of Franklin's BioMimetic Therapeutics (Ticker: BMTI), has filed a trading plan that will let it systematically raise that stake to up to 25 percent. SEE ALSO: How Novo has been adding to its BMTI holdings
Dec 9, 2009 7:59 AM
Company starts enrolling for injectable product trials in Canada
Nov 5, 2009 11:18 PM